BioUtah News

Inherent Biosciences raises Series A funding led by Propel Bio Partners to redefine the path to parenthood by elevating the standard of care in male reproductive health

Salt Lake City, Utah /PRNewswire/ — Inherent Biosciences, the first Utah company involved in commercializing a diagnostic in…
BIOHIVE STEM SEPTEMBER KICK-0FF

Last week, BioHive kicked off its celebration of “STEM September” with an evening of networking in downtown Salt…
Rep. Burgess Owens Spends a Day in the BioHive

Utah life sciences companies took center stage September 2, as U.S. Representative Burgess Owens (R-UT) toured Canyon Labs,…
New Liquid Embolic Multi-Center Trial Successfully Enrolls Final Patient

New Liquid Embolic Multi-Center Trial Successfully Enrolls Final Patient GPX® Trial Completes Enrollment Demonstrating Successful Tumor Uses and…
Senator Mike Lee Spends a Day in the BioHive

U.S. Senator Mike Lee (R-UT) on August 15 spent the day connecting with Utah’s life sciences community, known…
Halia Therapeutics Promotes Targeting the NLRP3 Inflammasome for Alzheimer’s Disease Treatment

Halia Therapeutics, the first biotechnology company to target NEK7 to block the assembly of the NLRP3 inflammasome complex,…
Renalytix Business Update

Based on recently secured private payer and Medicaid insurance coverage contracts for KidneyIntelX, Renalytix plc is disclosing that…
Nomi Health Adds Access to Novavax COVID Vaccine in Utah

Nomi Health, a direct healthcare company dedicated to improving access and lowering costs in the healthcare system, has…
Additional Patent Protection For Exoskeleton Focal-Force Angioplasty Platform Granted by the U.S. Patent Office

Transit Scientific, a Utah-based medical device company, today announced additional U.S. patent protection has been issued from the United States Patent…
Senate Passes Inflation Reduction Act – Sens. Lee, Romney Oppose

After an all-night session, the Senate on Sunday passed a sweeping, $740 billion reconciliation package titled the “Inflation…
Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX™ with Primary Care Physicians

98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult…
Sumitomo Pharma Oncology Receives Orphan Drug Designation for DSP-5336, an Investigational Menin and Mixed-Lineage Leukemia Binding Protein for Treatment of Acute Myeloid Leukemia

Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics has announced the U.S. Food and…